Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow NKGen Biotech, Inc.

Get SEC filing alerts via email and in your feed for NKGen Biotech, Inc.

NKGN NKGNW

NKGen Biotech, Inc.

About NKGen Biotech, Inc.

NKGen Biotech develops off-the-shelf and autologous natural killer (NK) cell therapies for neurodegenerative and oncological diseases. Utilizing proprietary manufacturing processes, the company produces highly active, cryopreserved NK cells designed for scalable, durable, and effective immune-based treatments. Focused on clinical development and strategic collaborations, NKGen aims to transform cellular immunotherapy with innovative, scalable solutions targeting cancer and neurodegenerative conditions.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from NKGen Biotech, Inc.

1
1
NKGen Biotech, Inc. NKGen Biotech Reports $15.4 Million Net Income Turnaround and FDA Clearance for Alzheimer’s Therapy

Via official filing (AI summary) | 5 months ago | 0 comments

2
1
NKGen Biotech, Inc. NKGen Biotech Reports $44.3M Net Loss for 2024, Announces Strategic Developments

Via official filing (AI summary) | 8 months ago | 0 comments

3
1
NKGen Biotech, Inc. NKGen Biotech Reports $6.6M Net Income in Q3 2024, Significant Turnaround from Previous Year

Via official filing (AI summary) | over 1 year ago | 0 comments

4
1
NKGen Biotech, Inc. NKGen Biotech Reports Significant Net Loss and Working Capital Deficit in Q2 2024

Via official filing (AI summary) | almost 2 years ago | 0 comments